title: Label-free screening assays: a strategy for finding better drug candidates.
abstract: The last 10 years have seen advances in automation and high-throughput biochemistry in the drug-discovery arena. However, these advances have not led to improvements in drug-discovery success. Drug programs must find new ways to identify superior compounds. Advances in label-free assay technologies may provide advantages needed for improved drug discovery. In this article, we will discuss high-throughput MS, a technology that allows screening with native substrates and with targets inaccessible to standard assay formats. We will then discuss cell-based label-free biosensors, focusing on the increased information content available when using these platforms. We will conclude with speculation on the future and ways to obtain relevant biological information early in development to ensure the best compounds are promoted to medicinal chemistry campaigns.
authors.affiliation: New Lead Discovery, Merck Research Laboratories, Kenilworth, NJ 07033, USA. charles.lunn@merck.com
authors.forename: Charles A
authors.initials: CA
authors.lastname: Lunn
mesh_terms: D000818:Animals; D001331:Automation; D015374:Biosensing Techniques; D055808:Drug Discovery; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D057166:High-Throughput Screening Assays / Q000379:methods*; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods*; D015394:Molecular Structure; D004364:Pharmaceutical Preparations / Q000737:chemistry*
chemical_list: D004364:Pharmaceutical Preparations